Westborough, Mass., March 3, 2021 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the targeted inhibition of coagulation Factor XIa, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial […]
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
 Clinical and preclinical data published in Critical Care Explorations demonstrate that EP-7041 has the ability to inhibit ECMO-related thrombosis while minimizing the risk of unwanted bleeding   Westborough, Mass., Sept. 17, 2020 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the inhibition of coagulation […]
Anticoagulation with the Novel, Small-molecule Factor XIa (fXIa) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model

Publications

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose-escalation phase I study

Frunexian administration in healthy Chinese volunteer adults exhibits favorable safety profiles with no bleeding events, predictable PK, and dose-proportional PD.

Our results position frunexian as a promising candidate for anticoagulant therapy and support its initiation of phase II clinical trials.

Download as PDF

EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation

Selective inhibition of FXI/FXIa is an appealing strategy for antithrombotic therapy during ECMO. The current standard of care for therapy is UFH despite the common thrombotic and hemorrhagic complications that accompany its use. Inhibition of FXI/FXIa, such as with EP-7041, offers a potentially novel approach to reducing the imbalance between procoagulant and anticoagulant factors in ECMO, and thorough research in this setting is warranted.

Download as PDF

Phase 1a/1b Study of EP-7041: A Novel, Potent, Selective, Small Molecule FXIa Inhibitor

Phase 1 results suggest the PK/PD profile of EP-7041 is ideal in acute care hospital settings where patients are at risk of thromboembolic events.

Download as PDF